Home › Conditions › Giant Cell Arteritis
Rheumatology
Giant Cell Arteritis
GCA — large-vessel vasculitis in >50s: new headache, scalp tenderness, jaw claudication, raised ESR/CRP. Visual symptoms = impending irreversible blindness — give IV methylprednisolone immediately, before any confirmatory test. Steroids do not obscure biopsy for 2–6 weeks.
GCA Fast-Track Pathway
The pathway
Recognise
- Age >50 + new headache
- Jaw claudication (most specific), scalp tenderness
- Visual symptoms: amaurosis fugax, diplopia, blur
- ESR/CRP raised (normal in ~5%)
Treat immediately
- Visual symptoms → IV methylprednisolone 500mg–1g OD × 3 days
- No visual symptoms → prednisolone 40–60mg PO daily
- Never wait for biopsy
Same-day referrals
- Visual symptoms → ophthalmology same day
- All → rheumatology fast-track GCA pathway
Confirm
- Temporal artery US — halo sign
- Biopsy within 2 weeks of steroids (skip lesions occur)
Protect & package
- Aspirin 75mg (local policy)
- PPI + bone protection + glucose monitoring
- Watch the fellow eye
Taper slowly
- Months–2 years of steroids, rheumatology-led
- Tocilizumab/methotrexate for relapsing disease
- PMR overlap in 40–60%
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Methylprednisolone | 500mg–1g OD × 3 days | IV | For any visual involvement. Then convert to high-dose oral. |
| Prednisolone | 40–60mg OD | PO | Uncomplicated GCA without visual symptoms. |
| Aspirin | 75mg OD | PO | May reduce ischaemic events — check local policy + GI cover. |
| Alendronic acid + Ca/vit D | 70mg weekly | PO | Bone protection for prolonged steroids. |
When to escalate
- Any visual symptom — IV steroids now + same-day ophthalmology
- Fellow-eye symptoms developing on treatment
- Limb claudication / aortic involvement suspected — vascular imaging
- Relapse during taper — rheumatology
Reference: BSR GCA Guidelines 2020 / EULAR imaging recommendations
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.